BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6173369)

  • 1. Alteration of membrane-associated enzymes in drug-resistant sublines of mouse lymphoblastoma L5178Y cells.
    Sugimoto Y; Nishimura T; Suzuki H; Tanaka N
    J Antibiot (Tokyo); 1981 Sep; 34(9):1200-5. PubMed ID: 6173369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
    Tanaka N
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms].
    Tanaka N
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1094-106. PubMed ID: 6191673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation, drug sensitivity, and some biochemical and genetical properties of macromomycin-resistant mouse lymphoblastoma L5178Y cells.
    Suzuki H; Sugimoto Y; Tanaka K; Nishimura T; Tanaka N
    J Antibiot (Tokyo); 1984 May; 37(5):602-9. PubMed ID: 6547433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug sensitivity and some characteristics of a bleomycin-resistant subline of mouse lymphoblastoma L5178Y cells.
    Suzuki H; Nishimura T; Tanaka N
    J Antibiot (Tokyo); 1981 Sep; 34(9):1210-2. PubMed ID: 6173370
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
    Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
    J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of action and resistance of antineoplastic agents].
    Tanaka N
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2245-51. PubMed ID: 6195971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of adriamycin resistance in a subline of mouse lymphoblastoma L5178Y cells.
    Nishimura T; Suzuki H; Muto K; Tanaka N
    J Antibiot (Tokyo); 1979 May; 32(5):518-22. PubMed ID: 583339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of plasma membrane of drug-resistant tumor cells: 230-kilodalton protein identified by monoclonal antibody.
    Sugimoto Y; Suzuki H; Tanaka N
    Biochem Biophys Res Commun; 1983 Aug; 114(3):969-75. PubMed ID: 6577861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
    Coley HM; Twentyman PR; Workman P
    Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
    Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
    Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity.
    Hori S; Shirai M; Hirano S; Oki T; Inui T; Tsukagoshi S; Ishizuka M; Takeuchi T; Umezawa H
    Gan; 1977 Oct; 68(5):685-90. PubMed ID: 579346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of erythrocyte ATPase activity by aclacinomycin and reverse effects of ascorbate on ATPase activity.
    Kitao T; Hattori K
    Experientia; 1983 Dec; 39(12):1362-4. PubMed ID: 6317432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
    Umezawa K; Kunimoto S; Takeuchi T
    Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
    Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
    Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
    Burres NS; Myers MT; Sartorelli AC
    Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines.
    Kunimoto S; Miura K; Umezawa K; Xu CZ; Masuda T; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1984 Dec; 37(12):1697-702. PubMed ID: 6526737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma.
    Sugimoto Y; Hirakawa Y; Tanaka N; Tahara M; Sato I; Nishimura T; Suzuki H; Tanaka N
    Cancer Res; 1986 Nov; 46(11):5646-8. PubMed ID: 3463416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells.
    Ganapathi R; Grabowski D; Schmidt H; Bell D; Melia M
    Cancer Res; 1987 Jul; 47(13):3464-8. PubMed ID: 2884031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.
    Scott CA; Westmacott D; Broadhurst MJ; Thomas GJ; Hall MJ
    Br J Cancer; 1986 May; 53(5):595-600. PubMed ID: 3718817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.